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Received July 11, 2012; accepted October 1, 2012AbstractImage-guided tumor ablation for lung malignancies has emerged as a treatment modality for medically inoperable patients. Overall, image-
guided lung tumor ablation is a minimally invasive procedure that has an acceptable safety profile and less impact on lung function. This is
important for patients with poor pulmonary and/or cardiac functions or with multiple comorbidities, which prevent them from undergoing
surgery, chemotherapy, and radiation therapy. Herein, we review the principle, techniques, clinical application, and patient outcomes of image-
guided lung tumor ablation.
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The lungs are a common site where malignancy occurs
frequently. Lung cancer is the primary cancer, with the highest
mortality rate being reported in Taiwan; it accounted for 20%
of all cancer deaths in 2010.1 Although the 1-year survival rate
for lung cancer has increased, the overall lung cancer survival
rate remains low with the existing treatment methods; a 17%
overall 5-year relative survival rate has been reported for all
stages combined, a 52% survival rate for localized disease, a
25% survival rate for regional disease, and a 4% survival rate
for distant disease.2 The lungs are also a common site for the
spread of metastatic tumor that originates from other parts of
the body. Approximately 20e50% of patients who die from
tumor malignancies are found to have pulmonary metastases.3
Surgical resection is the first-line treatment for early-stage
non-small-cell lung cancer (NSCLC), and pulmonary meta-
stasectomy is performed for certain primary tumors such as
hepatocellular carcinoma; in general, metastasectomy is* Corresponding author. Dr. Ming-Huei Sheu, Department of Radiology,
Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112,
Taiwan, ROC.
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http://dx.doi.org/10.1016/j.jcma.2013.03.004associated with prolonged survival.4 However, only 15% of
lung cancer patients have localized disease for which surgery
is a treatment of option. This is further complicated by a
decrease in lung function after surgery, which results in a
mean change in forced expiratory volume in 1 second (FEV1)
in 11e25% of patients after lobectomy, in 11e13% of patients
after segmentectomy, and in 9% of patients after wedge
resection.5,6 A proportion of individuals with low pulmonary
reserve do not meet the criteria for a lung operation, as defined
by the American College of Surgeons Oncology Group/Na-
tional Institutes of Health (NIH) Inoperability Criteria for
Lung Surgery.7
Medically inoperable patients account for 85% of all lung
cancer patients, and may need systemic chemotherapy or
external-beam radiation therapy. Radiation therapy has tradi-
tionally been used for patients with medically inoperable lung
cancer at clinical stage I and clinical stage II. Despite the
development of modern radiotherapy techniques such as
intensity-modulated radiation therapy, radiation to the lung
tissue, which has a low dose tolerance, may still be damaging.
Pneumonitis induced by radiation therapy occurs in more than
16% of patients when the V20 exceeds 22%, which may cause
serious respiratory distress, requiring hospitalization and
intubation, and can be fatal.8 Moreover, lung function mayhinese Medical Association. All rights reserved.
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may decline by 10% after 12e18 months of radiation therapy.9
These midterm complications and long-term sequelae limit the
use of radiation therapy in patients who have poor cardio-
pulmonary function. Additionally, approximately 43% of pa-
tients with lung cancer have a poor performance status of 2e4,
which prevents them from receiving surgical, radiation, or
chemotherapy treatment, resulting in a bleak 5-year survival
rate. Therefore, development of less invasive treatment mo-
dalities for patients with localized primary disease is
important.
Tumor ablation is a minimally invasive and relatively safe
procedure that can be a treatment option for patients who are
medically inoperable due to their poor pulmonary reserve.
Ablation refers to direct application of chemical or thermal
therapies to a specific focal tumor (or tumors) to achieve
eradication of the tumor or its substantial destruction.10 The
most contemporary tumor ablation technique is thermoa-
blation; the subtypes are radiofrequency ablation (RFA), mi-
crowave ablation (MWA), and cryoablation, which are named
according to their energy sources. Ablation techniques used
for lung tumors are of two types: image-guided (percutaneous)
and thoracoscopic lung tumor ablation. Image-guided lung
tumor ablation techniques share the common feature of an
energy generator in that it transfers the energy source to the
tumor by an image-guided, inserted, needle-like energy
“applicator” for a certain period of time, which results in
tumor destruction. Ablation has several advantages, including
selective damage, minimal morbidity and mortality, decreased
loss of lung function (because much of the normal lung tissue
is spared), repeatability, lower cost, excellent monitoring
during treatment, increased quality of life with less pain, and
shorter hospital stays.7 The present review article covers the
clinical application, mechanism, techniques, and outcomes of
image-guided ablation of lung tumor.
2. Clinical application
Currently, lung tumor ablation is applied to primary lung
cancer and metastatic lung malignancies for curative, symp-
tom relieving, and cytoreduction purposes.11 Interdisciplinary
coordination plays a major role in the selection of patients.
Curative ablation is indicated for stage I primary lung cancer
patients who are medically inoperable due to their poor pul-
monary functional reserve or cardiac comorbidities. Ablation
is also performed in patients with lung metastases generated
from colorectal and renal cell carcinoma, melanoma, hepato-
cellular carcinoma, and sarcoma primary tumors. A tumor size
of 3.5 cm and the tumor number of 5 are generally considered
to be the upper limits for ablation.12 Patients with symptoms
such as chest wall pain due to tumor invasion, hemoptysis, and
coughing can also be relieved completely or partially by tumor
ablation.13 A combination of ablation therapies for advanced
lung cancer and metastatic lung malignancies may also pro-
vide cytoreduction.14,15
The absolute contraindication for image-guided lung tumor
ablation is the presence of uncorrectable coagulopathies. Aninternational normalized ratio of >1.5, an activated partial
thromboplastin time of >1.5 times the normal value, or a
platelet count of <50,000/mL should all be considered for
correction. Plavix and aspirin should be withheld for 5 days.16
Relative contraindications include a poor patient performance
status of 3 or more and very limited life expectancy in the
Eastern Cooperative Oncology Group.12 Although ablation has
a limited effect on pulmonary function, a low FEV1 of less
than 0.6 L is considered a relative contraindication.17
3. Radiofrequency ablation3.1. PrincipleRadiofrequency is the frequency of oscillation in the range
of 3 kHze300 GHz. The RFA applicator serves as an
active electrode, and the reference electrode is the grounding
pad. In modern RFA, electric fields are established
between electrodes oscillate within the radiofrequency range
(375e500 MHz). Ions in the tissue then oscillate with the
oscillating electric fields, and their friction generates heat.
The heat is then dispersed gradually through the tissue by
conduction. Additionally, coagulation necrosis occurs after a
period of RFA application. At the tumor site, if the tissue
temperature remains at approximately 45C for several hours,
irreversible cell damage occurs; at 50C permanent damage
occurs within a few minutes; at 60C coagulation is induced
almost instantly; and at more than 100C the tissue will
vaporize and carbonize. Because carbonizing, also called
charring, impedes heat conduction, which plays a major role
in heat dispersion throughout the entire lesion, the ideal
therapeutic temperature range for RFA is 60e100C.5,18 The
extent of tissue destruction by ablation is called the ablation
zone.3.2. Equipment and techniquesCurrently, there are three major types of equipment systems
for RFA: a multitine electrode with temperature control, a
multitine electrode with impedance control, and an internally
cooled straight electrode. Each type of device consists of an
electrical generator, a needle electrode, and a ground pad. The
electrode diameter ranges from 14 gauge to 17 gauge. The
maximal output of the generator is approximately 200 W
(Fig. 1).
Prior to ablation surgery, patients fast overnight and have
intravenous access established. The grounding pads are
attached to their thighs, and the skin of the planned insertion
site is then prepped. Under local anesthesia with or without
conscious sedation, the electrode is placed under the guidance
of computed tomography (CT). In some institutions, CT-
fluoroscopy is utilized to achieve fast and precise electrode
insertion. The generator is then turned on to produce the RF
electric fields, and heat is generated at the target lesion. After a
period of ablation, the patient is transferred to the recovery
room for observation, and chest radiography is performed a
few hours after the procedure. If no pneumothorax or
Fig. 1. Tip of the electrodes for radiofrequency ablation. (A) The multitines of
the 14-gauge retractable multitine electrodes with an umbrella diameter of
4.0 cm (LeVeen Needle Electrode; Boston Scientific, Natick, MA, USA).
(B) The tip of the 17-gauge straight electrode with a 2-cm active tip with an
internally cooled system (Cool-tip ACT electrode; Covidien, Boulder, CO,
USA).
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day or after overnight observation.
In a study, an observation of the microscopic infiltration of
tumor cells surrounding the main tumor revealed that the mean
value of microscopic extension was 2.69 mm for lung
adenocarcinoma and 1.48 mm for lung squamous cell carci-
noma. Thus, an ablation zone covering a margin of 5e10 mm
beyond the visualizable tumor border is suggested.19 The
actual ablation zone may be estimated by the extent of groundFig. 2. Serial images of the radiofrequency ablation for a 76-year-old female who h
the lesion (arrow). (B) An electrode in the lesion with perilesional ground glass o
computed tomography (CT) image 1 week after ablation showed cavitation of ablati
noted (arrow). (D) A CT image 1 month after the procedure showed that the ablati
bubbles (arrow).glass opacity surrounding the lesion during RFA (Fig. 2). A 5-
mm ground glass rim covering the lesion in the immediate
postprocedural CT images suggests a good chance of complete
treatment.13 For large tumors, multiple overlapping ablations
are used to achieve an adequate ablation zone. Precise elec-
trode placement is critical for achieving the planned over-
lapping zone accurately, which can sometimes be difficult;
therefore, a detailed preprocedural planning and monitoring
during the procedure are important.
Several factors affect the ablation zone in lung tumor RFA.
Vessels with flowing blood have a heat sink effect, removing
heat from the region adjacent to the ablated site, which de-
creases the size of the ablation zone. This effect appears to be
related to the vessel size and was observed consistently in
vessels with diameters larger than 4 mm.20 The air in the
pulmonary parenchyma acts as an insulator to both heat and
electric current conductions. Moreover, the ventilated bron-
chus removes the applied heat in a way similar to that of an
air-cooled radiator. Thus, inserting the electrode precisely into
the center of the planned ablation zone is important to obtain
an optimal result.3.3. Patient outcomeA meta-analysis study by Zhu et al21 describes the com-
plications of RFA for lung tumors, which includead colorectal cancer with lung metastasis. (A) A preprocedural image showing
pacity (arrowheads), which provides an estimate of the ablation zone. (C) A
on zone (arrowheads) covering the original tumor (asterisk). Pleural effusion is
on zone is of low density, lacks nodular enhancement, and contains small gas
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pneumothorax requiring drainage in 9.5% (range,
3.3e38.9%), pneumonia in 2.2% (range, 6e12%), pulmonary
abscess in 0.6% (range, 0e6.6%), pleural effusion in 14%,
pleural effusion requiring chest drainage in 0.1%, hydro-
pneumothorax in 0.2%, hemothorax in 0.7% (range
0e16.7%), intrapulmonary bleeding in 1.6% (range, 0e11%),
hemoptysis in 3.4% (range, 0e18.2%), pleuritis chest pain in
2.9% (range, 0e24%), cough in 2.1% (range, 0e33%), fever
in 4.3% (range, 0e22%), and acute respiratory distress syn-
drome in 0.1% of the procedures. Additionally, two cases of
tumor seeding have been reported,18 with pulmonary embolus
being noted in 0.1% of patients. Procedure-related complica-
tions, with an adverse event grade of higher than 3, occurred in
approximately 6% of the cases.22 Overall complication rates
of RFA for lung tumor are similar to those of percutaneous
lung biopsy.
Rare complications of RFA for lung tumor include bron-
chiolitis obliterans and organizing pneumonia, which are re-
ported to have an incidence of 0.4%; the treatment involves
pulse steroid therapy if the symptoms are severe.23 Uninten-
tional burns are rare, and burns of the skin and of organs
adjacent to the lesion are considered as two different types of
burns. Attachment of the ground pad away from the metallic
prosthesis prevents concentration of the energy, and avoiding
excessive hair and sweating at the grounding pad attachment
site decreases the adhesion of the ground pad, which may help
decrease the chance of skin burns.11,24 Special caution is
needed when the ablation is prolonged or has a high current.
Burns to nontargeted organs are more likely when they are
within 1 cm of the target lesion11; hollow organs and di-
aphragms are the vulnerable organs.25
Few cases of mortality have been reported. Herrera and
colleagues26 reported a death as a result of fatal hemoptysis
after ablation of a central pulmonary nodule in a patient who
had received brachytherapy recently. Vaughn and colleagues27
described a case report of an elective intraoperative RFA of
primary lung cancer in a patient who suffered a massive
intraparenchymal and an extrapleural pulmonary hemorrhage;
the patient died from aspiration pneumonia. Previous radiation
therapy was reported to be a risk factor for the development of
fatal interstitial pneumonia after radiofrequency.28 The
procedure-related mortality was reported to be 0.6%.29
Ambrogi et al30 studied the change in lung function after
RFA for lung tumors and found that lung function was slightly
decreased at 1 month after the procedure and returned to
almost normal at 3 months after RFA. Similar findings were
reported in other studies, and this result is especially important
for patients with poor pulmonary reserve.31
CT is used to monitor response to therapy. A decrease in
tumor size and a lack of contrast medium enhancement in the
ablation zone indicate no local tumor progression. It is worth
noting that the appearance of the ablation zone changed with
time. The ablation zone was commonly found to be enlarged
in the immediate and 1-month follow-up CT images, and re-
ported to decrease in size at 3 months, 6 months, 9 months,
and 12 months by 6%, 11%, 14%, and 40%, respectively.32 Itis better to judge the treatment response between 1 month and
3 months after ablation than at 1 month. Cavitation and tiny
gas bubbles were commonly found at the ablation zone and
could be observed up to 1 year after ablation.33 In the mid- and
long-term follow-ups, no enhancement or thin rim enhance-
ment was noted in the lesion that was completely ablated,
whereas focal nodular enhancements of more than 15
Hounsfield units (HU) were considered to have local tumor
progression. Local tumor progression occurred in 31% of tu-
mors after ablation.22 The frequency of local tumor progres-
sion was found to be correlated significantly with size;
recurrence tended to be close to the ablated tumor site and
more frequent in larger tumors (>4 cm in diameter) and at
higher disease stages.34 Simon et al29 reported improved local
tumor progression-free rates for tumors <3 cm in diameter.
Proximity to vessels larger than 3 mm in diameter has also
been found to be associated with an increased risk of local
tumor progression.35 Tumors that are in contact with a bron-
chus larger than 2 mm in size have a reportedly poorer
response to RFA.36
The survival rates of stage I lung cancer patients is
78e94% at 1 year, 57e86% at 2 years, 36e74% at 3 years,
67% at 4 years, and 61% at 5 years.22,29,37 The cancer-specific
survival rates are 100%, 93%, 80%, 80%, and 74% at 1 year, 2
years, 3 years, 4 years, and 5 years, respectively. The disease-
free survival percentages are 82%, 64%, 53%, 46%, and 46%
at 1 year, 2 years, 3 years, 4 years, and 5 years, respectively.
With respect to survival of a patient receiving radiotherapy, a
meta-analysis showed that the 3-year overall survival rate of
stage I NSCLC patients receiving conventional external beam
radiation therapy is 34%.38 Patients receiving stereotactic
radiotherapy, a novel radiotherapy technique, have been re-
ported to have a survival rate of 81% or higher at 1 year and a
survival rate of 60% at 2 years.39 Essentially, RFA may offer a
benefit comparable to that of radiation therapy for patients
with inoperable stage I lung cancer.
RFA and sublobar resection have comparable efficacy. Lee
et al14 retrospectively compared survival in elderly patients
with primary NSCLC between those receiving surgical treat-
ment and those receiving RFA, and found that surgical treat-
ment alone yields a median survival time of 34 months,
whereas RFA alone yields a survival time of 28 months. The
difference is not statistically significant.
The combination of RFA with radiation therapy, brachy-
therapy, and systemic chemotherapy results in an increased
survival and local control of the lung malignancies.14,40,41
4. Microwave ablation4.1. PrincipleMicrowave frequencies refer to the region of the electro-
magnetic spectrum with frequencies ranging from 300 MHz to
300 GHz. Modern MWA utilizes devices that generate elec-
tromagnetic waves that have electric charge flipping in the
range of microwave frequencies, between 900 MHz and
2450 MHz.42,43 The electromagnetic wave has an electric
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wave frequency oscillating at 915 MHz, the charge changes
signs nearly 2 billion times per second. Water molecules
(H2O) are polar; the hydrogen side of the molecule has a
positive charge and the oxygen side has a negative charge.
When it interacts with a microwave, the molecule flips. The
fast movement of water molecules raises the temperature in
tissue and induces cellular death via coagulation necrosis.42
Due to the inherent properties of the microwave (no elec-
trical current being produced), the device does not need to be
grounded, abolishing the problem of grounding pad burns.
Additionally, microwave energy may be less likely to be
affected by charring and may thus provide better heating
around soft tissue nodules compared with RF energy. The heat
sink effect that is prominent in RFA is not only less likely in
MWA, but selective tracking of the ablation zone along the
blood vessel may actually increase the ablation zone.444.2. Equipment and techniquesCurrently, two microwave tumor ablation systems are
available in Taiwan (Evident; Covidien, Mansfield, MA, USA,
and AveCure; MedWaves, San Diego, CA, USA): one uses a
generator with a fixed frequency of 915 MHz and the other
uses one with variable frequencies in the range
908e920 MHz. The microwave energy applicator is called the
antenna, and the size of microwave antennas ranges from 12
gauge to 16 gauge. The active tip length is from 2 cm to 4 cm.
Through the exposed, noninsulated active tip, a microwave
generator emits an electromagnetic wave via the image-guided
inserted antenna to achieve ablation.424.3. Patient outcomeAfter MWA, the ablated foci undergo a cavitary change of
43e50% in which the airefluid level is 14%. Pleural thick-
ening is observed in 44% of patients. Initially, the ablation
zones are enlarged, up to a diameter of 0.65 cm, and then
decrease gradually by consolidation.45
In current studies, no cases with 30-day mortality were
reported. Approximately 33e39% of sessions resulted in
pneumothorax. Approximately 0e12% of procedures required
chest tube insertion [Common Terminology Criteria for
Adverse Events (CTCAE) grade 2]. A skin burn was observed
in 3% of the patients attending all sessions, and one patient
required debridement (CTCAE grade 3). A total of 2% of
patients had postablation syndrome, while 2% of individuals
developed respiratory distress (CTCAE grade 4) and recovered
after 1 week.45,46 Mild pleural effusion without the need for
thoracocentesis was noted in 20e30% of patients.
The median time of first distant metastases is 16 months.
When the tumor size is larger than 3 cm, patients are more
likely to have recurrent tumor at follow-ups. The local control
rate is 67% at 1 year.45 In a series of nine patients with a mean
follow-up time of 3.6 months, Carrafiello et al46 reported a
local recurrence at 3 months after MWA in one patient.Wolf et al45 ablated 82 masses in 50 patients with a median
follow-up period of 10 months. The overall survival percent-
ages were 65%, 55%, and 45% at 1 year, 2 years, and 3 years,
respectively. The cancer-specific survival rates were 83%,
73%, and 61% at 1 year, 2 years, and 3 years, respectively. A
KaplaneMeier analysis of all-cause mortality revealed a me-
dian time to death of 19 months.
5. Cryoablation5.1. PrincipleCryoablation is a thermoablation technique in which a
freezing temperature is used to destroy tissue. Modern cry-
oablation techniques consist of alternative cycles of decreasing
temperature (freezing) and increasing temperature (thawing),
which cause direct cell and vascular injury. As the temperature
is lowered in the freezing range, water in the tissue is crys-
tallized. The ice crystals are first formed in the extracellular
spaces, increasing the extracellular osmolarity; as a conse-
quence, the water diffuses from the intracellular space into the
extracellular space. The cell then shrinks, and the cell mem-
branes are damaged. If the cooling is fast, intracellular ice is
formed in most of the cells at a temperature of 40C. The
shear force during ice formation disrupts the organelles and
cell membranes, resulting in cell death almost definitely.47
During thawing, when the temperature is between 20C
and 40C, the maximum direct cell injury, caused by the
process of fusing small ice crystals into a larger ice ball, re-
sults in abrasion and possible injury of the cell membrane. As
the temperature continues to rise, the ice at the extracellular
space will melt and cause a hypotonic condition, followed by
water entering the cell through the already injured cell mem-
brane. The cell will rupture eventually. Vascular injury begins
during the freezing phase at which the circulation ceases. After
thawing the tissue to a temperature of more than 0C, vaso-
dilatation with a hyperemic response damages the cell mem-
brane and causes edema. Then, aggregation of platelets and
thrombosis of the circulation occur, resulting in uniform ne-
crosis of the tissue.48
Experiments have shown that performing two ablation cy-
cles, each consisting of 10 minutes of freezing and 5 minutes
of thawing, using a single 2.4-mm cryoprobe results in an
ablation zone (with complete necrosis) with a mean diameter
of 2.4 cm  0.2 cm. Because this diameter is most closely
related to the 20C isotherm, the critical temperature for
inducing cellular death in the lung parenchyma is likely to be
approximately 20C.495.2. Equipment and techniquesIn cryoablation, the cryogen generates a low temperature in
the applicator (e.g., the cryoprobe) to destroy the tissue. The
currently available, third-generation cryoablation model uses
argon as the cryogen. The high-pressure argon gas from the
control unit passes into the inner chamber of the cryoprobe
prior to passing through a small nozzle into the larger outer
Fig. 3. Cryoprobes and ice ball. The upper applicator is a 20-cm-long cryo-
probe with a diameter of 2.4 mm, and a preformed ice ball was formed after 7
minutes in water. The lower applicator is a 15-cm-long cryoprobe with a
diameter of 2.4 mm (Cryocare System; Endocare, Inc., Irvine, CA, USA).
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effect, as the volume of argon expands, the temperature may
decrease to 187C. Helium gas acts as a heating source by
increasing the temperature up to 67C as volume is
increased.50 The diameter of the modern percutaneous cryo-
probes ranges from 1.47 mm (17 gauge) to 2.4 mm, and each
cryoprobe size has an ablation zone estimate. The control unit
may connect up to 25 cryoprobes simultaneously (Fig. 3).Fig. 4. Images of squamous cell carcinomas in an 83-year-old male. (A) A preproce
upper lobe (arrow). (B) An image during the freezing phase of the ablation cyc
(compared to other modalities), covering the lesion (arrowheads). (C) The ablation
the lesion. (D) Three days after the procedure, pleural effusion (arrow) was observ
ablation zone (arrowhead) showed involution with cavitation at 8 months after t
involution of the ablation zone (arrowhead).In the cryoablation procedure, the cryoprobe(s) is(are)
inserted into the lesion under CT guidance. The crystals
formed by freezing fuse as a well-demarcated volume of ice
ball, with a density between 0 HU and 50 HU when the ice
ball is in soft tissue or fat.51 Because the cytotoxic isotherm
curves (at 20C) occur approximately 3e5 mm inside of the
visualized ice margins, the zone of ablation can be estimated.
In a large tumor, inserting multiple cryoprobes and freezing
simultaneously produce a larger ablation zone.5.3. Patient outcomeComplications from cryoablation for lung tumor were re-
ported in three large series with 644 cases, 200 cases, and 193
cases, with pneumothorax occurring in 12e62%, and CTCAE
grade 2 or more in 4%. Hemoptysis was noted in 37e62% of
cases, and CTCAE grade 2 hemoptysis was noted in 0.6%.
Pleural effusion occurred in 14e71%. Fever was noted in
3e42%, hypertension in 33%, and subcutaneous emphysema
in 5% of cases. Skin injury was noted in 5% of cases, and the
percentage of complications (CTCAE grade of more than 3)
was approximately 1.5%. Lung infection occurred in 6.7% of
cases. Brachial plexus injury and recurrent laryngeal nerve
paralysis occurred in 1% and 0.5% of cases, respectively. The
mortality rate was 0.6%.52,53
Cavitation is the most common postablation finding, which
occurred in 77% of cases. In most cases of tumor ablation, the
ablation zones were initially larger than the original tumor.dural axial chest computed tomography (CT) image showed a nodule at the left
le showed a low-density elliptical ice ball, which is unique to cryoablation
zone is estimated by the consolidation rather than the ground glass surrounding
ed, which is a common finding in cryoablation for subpleural lesions. (E) The
he procedure. (F) The CT at 12 months after the procedure showed further
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months. The remaining lesions without local recurrence might
decrease in size or maintain a stable size (Fig. 4).54
CT is used to monitor the local tumor progression, usually
with the same criteria as used inRFA. Immediate postprocedural
positron emission tomography (PET)/CT is unable to monitor
the immediate therapeutic effect.55 The reported local control
rates for the cryoablation for stage I lung cancer with an average
tumor size of 1.4 cm are 97%, 97%, and 97% at 1 year, 2 years,
and 3 years, respectively. The cause of local tumor progression
was an insufficient margin of ablation. A total of 27% of the
patients developed recurrence at a site other than the local site at
a median follow-up period of 23 months.56
The overall survival rates were 95% at 1 year, 88% at 2
years, and 88% at 3 years. The disease-free survival percent-
ages were 91%, 78%, and 67% at 1 year, 2 years, and 3 years,
respectively.56 According to recent reports, the efficacy of lung
tumor cryoablation is comparable with RFA and sublobar
resection. Zemlyak et al7 retrospectively compared sublobar
resection, RFA, and cryoablation for 64 patients with NSCLC.
The survival percentages were 87%, 87%, and 77% for sub-
lobar resection, RFA, and cryoablation, respectively. No sig-
nificant difference was noted between the three groups. For
surgical therapy, RFA, and cryoablation, respectively, the
cancer-specific 3-year-survival percentages were 91%, 88%,
and 90%, and the disease-free survival percentages were 61%,
50%, and 46%.
6. Comparison and limitations6.1. Comparison according to the ablation modalityUnlike RFA, cryoablation does not result in substantial
collagen damage and appears to be a better option for patients
with extensive emphysema.7 Cryoablation also has potential
applications in the lesions that are adjacent to the diaphragm
where use of other modalities may cause diaphragmatic
rupture.57 MWA has a larger ablation zone than RFA and a
reduced heat sink effect, which makes it a better fit for patients
who have larger tumors or tumors that are close to larger vessels
because it can provide more complete ablation.44,58 Radio-
frequency has the advantages of a low cost and relatively round
ablation zone, which may be effective for medium-sized tumors
(1.0e2.5 cm) that can be covered with fewer electrodes.6.2. Limitations of image-guided tumor ablationLung tumor ablation has several limitations. First, because
local tumor ablation can destroy only the targeted tumor and
does not affect lymph node metastases, it is important to
perform local tumor ablation only on patients who lack lymph
node metastases or have their lymph node metastases
controlled by another modality, such as radiation therapy, if
the aim of treatment is curative. Second, the application of
ablation for lesions near the mediastinum and lateral aspect of
the lung apex can be limited. When the lesions are near vital
structures such as the phrenic nerve and brachial plexus, theycan damage these structures, compromising their function.59
Third, pulmonary hilar lesions are difficult to target; they
usually have the same density as major vessels in the pul-
monary hilum under CT guidance. Therefore, an appropriate
positioning of the applicator for sufficient coverage of the
tumor, without puncturing the hilar vessels and causing sub-
stantial bleeding, is challenging. Fourth, ablating a superficial
lesion is challenging for cryoablation because the ice ball of
the cryoablation in most cryoprobes is elliptical, as it is
approximately 4e5 cm in the direction parallel to the cryo-
probes. As a result, the skin can easily be included in the ice
ball, causing skin injury, which may limit the application of
ablation for superficial lesions. Fifth, MWA may damage
nontarget tissue along the vessel as a result of the tracking of
the ablation zone along blood vessels; this may limit the
application of MWA. Sixth, in RFA, individual tines of mul-
titine electrodes are sometimes difficult to monitor precisely,
especially when used adjacent to vulnerable structures such as
the mediastinum and diaphragms, and the individual tines can
penetrate those structures and cause complications.25
In conclusion, image-guided tumor ablation is a minimally
invasive treatment option for selected inoperable patients with
lung malignancy. A prospective, randomized, controlled trial
is needed to further compare the outcomes of limited resec-
tion, stereotactic body radiation therapy, and different ablation
methods. However, the current evidence reveals a relatively
safe profile and substantial efficacy of lung tumor ablation for
tumor control and patient survival. These results are particu-
larly relevant for treating patients with pulmonary comorbid-
ities as well as localized or limited malignant lung disease
(tumors being less than 3.5 cm in size and located in the pe-
ripheral two-thirds of the lungs) who otherwise have no
treatment options.
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